Breakfast/registration

Introduction & Meeting Objectives
Co-Chairs: David Maloney & Sarah Nikiforow

Session 1:  Emerging CARs and future challenges in solid tumors
Chairs: Julian Molina 

• HER2-targeted CAR-macrophages for solid tumors: Matthew Angelos
• Migratory engineering of T cells for cancer therapy: Sebastian Kobold
• Solid tumor microvasculature challenges for lymphocyte delivery: Ulrich von Andrian

Panel discussion

Session 2: Genitourinary cancers
Chairs: Vivek Narayan  

• Next steps in safety and efficacy for CAR-T in prostate cancer: Vivek Narayan
• NK cells for GU malignancies: Nicholas Zorko
• Novel redirected T-cell immunotherapies for advanced solid tumors: Saul Priceman
• Autologous T-cells engineered with T-cell receptors (TCRs): David Hong

Panel discussion

Break

Session 3: CAR-T clinical advances in lung cancer
Chairs:  Prasad Adusumilli 

• Updates on TIL therapy in lung cancer: Adam Schoenfeld
• Mesothelin-targeted CAR T-cell therapy: Prasad Adusumilli
• The challenges and the future of cell therapy in lung cancer: William Go

Panel discussion

Session 4: Ovarian cancers
Chairs: Payal Shah 

• Receptor-alpha redirected T-cells for ovarian cancer: Payal Shah
• Metabolic reprogramming to enhance adoptive cell therapy in ovarian cancer: Marion Curtis

Panel discussion

Session 5: Logistics/manufacturing
Chairs: David Maloney

• CAR T-cell studies in solid tumors – logistic issues: Julian Molina
• Manufacturing/FACT and ASTCT 80/20: Sarah Nikiforow

Panel discussion

Lunch

Keynote talk: An FDA perspective on CAR-T/cellular therapies in cancer: Asha Das

Session 5: Gastrointestinal cancers
Chairs: Diane Simeone & Joel Randolph (Randy) Hecht

• GI malignancies; I-O to cell therapy; I-O/T-VEC, BiTEs/TCRs: Joel Randolph (Randy) Hecht
• scSeq in pancreatic cancer; pancreatic cancer tumor microenvironment: Diane Simeone
• TAC01-HER2 cell therapy in HER2+ solid tumors: Benjamin Schlechter
• 2-specific chimeric antigen receptor T-cell therapy for patients with advanced gastric & pancreatic adenocarcinoma: Zhaohui Jin
• Novel CDH17 CAR-T for gastrointestinal tumors: Xianxin Hua

Panel discussion

Session 6: Head/neck and CNS cancers
Chairs: Rizwan Romee & Kedar Kirtane

• Development of novel therapeutics for H&N cancer: challenges and opportunities: Jong Chul Park
• Cellular immunotherapy in head and neck cancers: Kedar Kirtane
• Engineering NK cells for enhanced solid tumor targeting: Rizwan Romee

Panel discussion

Break

Session 7: Melanoma, sarcomas
Chairs: John Mullinax 

• Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma: Sebastian Klobuch
• Intraoperative principles related to TIL procurement for solid tumors: John Mullinax

Panel discussion

Day 1 wrap-up

Welcome reception

Breakfast & registration

Meeting objectives, introduction
John Gribben & David Maloney

Session 9: Current challenges
Chairs: David Miklos & Marco Davila

• Suppression mechanisms of CAR-T cells: Marco Davila
• Enforcing memory programs to enhance CAR-T persistence: Evan Weber
• Cladribine & cyclophosphamide lymphodepletion for the CAR T-cell treatment of hematologic malignancies: Filip Ionescu
• Single-cell analysis of CAR-T response and toxicity: Michael Green

Panel discussion

Session 10: Toxicity
Chairs: Caron Jacobson & Marion Subklewe

• CRS/ICANS prophylaxis attempts: Matthew Frigault
• Update on management of neuro-toxicities/CRS in CAR-T: Bianca Santomasso

 Panel discussion

Break

Session 11: CAR-T in ALL
Chairs: Noelle Frey & Bijal Shah

• Long term outcomes for recipients of CTL019 (tisagenlecleucel): Shannon Maude
• ZUMA-3 – brexucabtagene autoleucel for adult ALL: Bijal Shah
• CD19-targeted CAR T-cell in R/R B-cell ALL/Auto: Claire Roddie
• Dual-targeting with CAR-Ts using a co-administration approach: Regina Myers

Panel discussion

• PLAT-05 Trial; dual-targeting with CAR-Ts using a co-transduction approach: Rebecca Gardner
• Bispecific LV20.19 and trispecific duo CAR20.19.22 for B-cell malignancies: Nirav Shah
• CAR-T for T-ALL: Maksim Mamonkin

Panel discussion

Lunch

Session 12: CAR-T in AML
Chairs: Saar Gill & David Sallman

• Single-cell analysis to develop new CAR therapies for AML: Sebastian Kobold
• Leukemia-associated antigen-specific T-cells: Premal Lulla
• Outcomes in early-phase CAR-T clinical trials for R/R AML and MDS: David Sallman
• NK cell-based immunotherapy for patients with HR hematologic malignancies undergoing transplantation: Roman Shapiro
• With a little help from my friends – updates on bispecifics in AML: Marion Subklewe

Panel discussion

Session 13: CAR-T in lymphoma
Chairs: David Maloney & Frederick Locke

• Liso-cel for the treatment of B-cell lymphoma: Jeremy Abramson
• Brexucabtagene autoleucel in R/R MCL: Michael Jain
• CARs for primary CNS lymphoma: Caron Jacobson
• Alternative targets in lymphoma (CD22, ROR1): David Miklos
• CD20-targeted CAR-T: Mazyar Shadman

Panel discussion

• CRISPR-edited allogeneic anti-CD19 CAR T-cell therapy for R/R B-cell NHL: Loretta Nastoupil
• Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphoma: Laura Samples
• Bispecifics in DLBCL: Mazyar Shadman
• Bispecific treatments in FL and MCL: Tycel Phillips

Panel discussion

Special debate: CAR-T & bispecific antibodies – all panelists       

Session 14: Just in time/rapid manufacturing/in vivo – allo vs auto
Chairs: TBC

• Varnimcabtagene autoleucel for R/R B-cell malignancies: Valentín Ortiz-Maldonado

Panel discussion

Day 2 wrap-up

Faculty Dinner

Breakfast

Welcome

Keynote lecture: Driving CAR T-cells forward: Renier Brentjens

Discussion

Session 15:  CAR-T in multiple myeloma
Chairs: Yi Lin & Rafael Fonseca

• Updates from the Myeloma CAR-T Consortium: Doris Hansen
• Regulatory approved CAR-Ts, where are they headed? KarMMa-3, data for ide-cel and cilta-cel in earlier lines, and new correlates for CAR-T: Yi Lin
• Real-world safety & efficacy of ide-cel in patients with multiple myeloma: Krina Patel

Panel discussion

• BCMA and non-BCMA bispecific antibodies for multiple myeloma: Rafael Fonseca
• Mechanisms of resistance to BCMA-targeted therapy and impact of treatment sequencing: Nizar Bahlis
• AlloCART – will they be the solution to access in myeloma?: Sham Mailankody
• GPRC5D CAR-T in myeloma: Eric Smith

Panel discussion

Break

Session 16: CAR-T in CLL
Chairs: John Gribben & Tanya Siddiqi

• Immune resistance in CLL: Joseph Melenhorst
• Update on TRANSCEND – liso-cel in CLL/SLL: Tanya Siddiqi
• CART-19 with ibrutinib for the treatment of CLL: Saar Gill

Panel discussion

Final meeting summary & conclusions

Lunch (grab & go – in room)